Pharmacokinetic drug interactions with anti-ulcer drugs

The safety profile of any pharmacological agent is defined on the basis of its toxicity, tolerability and potential for pharmacokinetic and/or pharmacodynamic interactions with other compounds, which may belong to the same or to a different pharmacological class. Drug-drug interactions are important in clinical practice because short and long term therapeutic regimens frequently require coadministration of different drugs. The pharmacological treatment of gastric and duodenal ulcers (and of related syndromes) includes older and newer compounds, which have different mechanisms of action and exert different therapeutic effects. These compounds are widely prescribed in combination with other drugs being given for the treatment of concomitant diseases. This article reviews pharmacokinetic interactions with anti-ulcer drugs, paying particular attention to those which have clinically relevant adverse effects. Drugs mentioned in the literature as causing any pharmacokinetic interaction with anti-ulcer compounds are considered in this article.